PetVivo Holdings Earnings Call Transcripts
Fiscal Year 2026
-
Fiscal 2026 saw modest revenue growth, major product and technology launches, and strategic acquisitions, despite a wider net loss driven by lower-margin product sales and impairment charges. Regulatory milestones and new AI-powered platforms position the company for accelerated growth in expanding markets.
-
The presentation highlighted innovative joint health products, a soon-to-launch AI platform, and strategic acquisitions to expand both animal and human health pipelines. Key milestones include Canadian market entry, new clinical studies, and human FDA filings by 2027.
-
Innovative joint health solutions are gaining traction among veterinarians, with Spryng and PrecisePRP offering multimodal, less invasive alternatives to traditional treatments. Strategic distribution partnerships and upcoming clinical milestones are set to drive further adoption and market expansion.
-
Strategic alliances and new product launches drove platform advancement, with PetVivo AI showing strong early results and creating a high-margin recurring revenue stream. Revenues dipped 2% year-over-year, but gross margin remained robust at 62.2%.
-
Achieved record quarterly and first-half revenues, driven by strong distributor sales and new product launches. Expanded internationally, reduced liabilities, and advanced strategic partnerships and AI initiatives, with continued robust growth expected for fiscal 2026.
-
Revenue grew 141% year-over-year to $298,000, driven by expanded distributor sales and new product launches. Operating loss and net loss both improved, while cash position strengthened through financing. Strategic partnerships and product innovation position the company for continued growth.
Fiscal Year 2025
-
Spryng and PrecisePRP offer regenerative, long-lasting solutions for osteoarthritis in companion animals, supported by strong clinical results, broad distribution, and a robust IP portfolio. Strategic partnerships, international expansion, and ongoing R&D position the company for growth.
-
Fiscal 2025 delivered 17% revenue growth, improved margins, and reduced losses, driven by distributor expansion, cost controls, and new partnerships. Strategic financing and innovative product launches position the company for continued growth in a rapidly expanding animal health market.
-
Q3 saw a 191% sequential revenue increase to $583,000, driven by expanded distribution and high gross margins of 89.5%. Operating expenses and net loss improved year-over-year, while new partnerships and product launches position the company for further growth.
-
Board and auditor appointments were ratified, and Spryng continues to gain traction in the veterinary market with strong clinical results, expanded distribution, and ambitious sales growth targets. Financials remain robust with high margins and a flexible capital strategy.
-
Q2 FY2025 saw 62% sequential revenue growth, driven by distributor sales and cost reductions, with gross margin steady at 89.5%. The company targets over 1,500 clinics by year-end and expects FY2025 revenue to grow over 50% year-over-year.
-
Revenue grew 6% year-over-year to $124,000, driven by distributor sales, while gross margin remained strong at 89.5%. Operating expenses fell 28%, and net loss improved to $2 million. Expanded distribution, new leadership, and ongoing clinical studies support guidance for up to 100% revenue growth.
Fiscal Year 2024
-
Fiscal 2024 revenue grew 6% to $969,000, driven by distributor expansion and strong Spryng sales. Operating expenses rose 20%, leading to a net loss of $11 million. Cost reductions, new clinical data, and expanded partnerships position the company for improved performance.